Tripos Completes Acquisition of Optive Research, a Molecular Discovery Software Company
Tripos, Inc. announced that it has acquired privately held Optive Research, Inc., a recognized leader in developing innovative software for computer-assisted molecular discovery, for $4.75 million in cash and 599,521 shares of Tripos stock.
The cash portion of the deal was funded through a $4 million investment by Horizon Technology Finance, LLC and Sand Hill Capital through the issuance of $3.5 million of subordinated debt, 111,606 shares of common stock, and warrants to purchase 156,250 shares of common stock. Tripos expects this transaction to begin contributing to its operating income in 2005, and become accretive to net income by 2006. Seven Hills Partners acted as exclusive placement agent to Tripos in arranging this financing.
Most read news
Other news from the department business & finance
These products might interest you

Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management

LAUDA.LIVE by LAUDA
LAUDA.LIVE - The digital platform for your device management
Comprehensive fleet management options for every LAUDA device - with and without IoT connectivity

ACD Spectrus Platform by ACD/Labs
Software for Analytical Data Handling in R&D
Standardized Analytical Data Processing & Knowledge Management

ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration

ZEISS ZEN core by Carl Zeiss
ZEISS ZEN core - Your Software suite for connected microscopy in laboratory and production
The comprehensive solution for imaging, segmentation, data storage and analysis

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Accelrys Announces Pfizer Inc. as the First Member of the Enterprise Cheminformatics Consortium - Consortium to Drive the Evolution of Enterprise Cheminformatics Systems Using Open and Flexible Service-Oriented Architecture
The buzz on an amazing new mosquito repellent: Will it fly?
Orion sues generic drug companies in the U.S. to enforce patents for entacapone

Coordination chemistry of anions through halogen-bonding interactions
Katz_Group_of_Companies
GEA: Dr. Stephan Petri to continue as Member of the Executive Board until 2018

Rapid Change: Ceresana Analyzes the Global Market for Printing Inks

Recent research provides new data on chemical gardens, whose formation is a mystery for science
John_Lawrence_Smith
Serono and Evotec OAI sign assay development and screening services agreement
